Locoregional therapy in breast cancer patients treated with neoadjuvant chemotherapy

References

• Brackstone M, Fletcher GG, Dayes IS, et al. Locoregional therapy of locally advanced breast cancer: a clinical practice guideline. Current Oncol. 2014;22(Suppl 1):S54–S66.
   Google Scholar
• Buchholz TA, Lehman CD, Harris JR, et al. Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a national cancer institute conference. J Clin Oncol. 2008;26(5):791–797.
   PubMed Web of Science ®Google Scholar
• Recht A, Comen EA, Fine RE, et al. Postmastectomy radiotherapy: an American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology focused guideline update. Ann Surg Oncol. 2017;24(1):38–51.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov[Internet]. Bethesda (MD): National Library of Medicine (US). 2000 Feb 29 -. Identifier NCT01872975, Standard or comprehensive radiation therapy in treating patients with early-stage breast cancer previously treated with chemotherapy and surgery; 2013 Jun 7 [cited 2020 Oct 20]. Available from: https://clinicaltrials.gov/ct2/show/NCT01872975
   Google Scholar
• Ikeda T, Jinno H, Kitajima M. The evolution of primary chemotherapy in breast cancer treatment. Breast Cancer. 2004;11(2):148–155.
   PubMedGoogle Scholar
• Abdel-Wahab M, Wolfson A, Raub W, et al. The importance of postoperative radiation therapy in multimodality management of locally advanced breast cancer: a phase II trial of neoadjuvant MVAC, surgery, and radiation. Int J Radiat Oncol Biol Phys. 1998;40(4):875–880.
   PubMed Web of Science ®Google Scholar
• Huang EH, Tucker SL, Strom EA, et al. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol. 2004;2(23):4691–4699.
   Google Scholar
• McGuire SE, Gonzalez-Angulo AM, Huang EH, et al. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys. 2007;68(4):1004–1009.
   PubMed Web of Science ®Google Scholar
• Nagar H, Mittendorf EA, Strom EA, et al. Local-regional recurrence with and without radiation therapy after neoadjuvant chemotherapy and mastectomy for clinically staged T3N0 breast cancer. Int J Radiat Oncol Biol Phys. 2011;81(3):782–787.
   PubMed Web of Science ®Google Scholar
• Shim SJ, Park W, Huh SJ, et al. The role of postmastectomy radiation therapy after neoadjuvant chemotherapy in clinical stage II-III breast cancer patients with pN0: a multicenter, retrospective study (KROG 12-05). Int J Radiat Oncol Biol Phys. 2014;88(1):65–72.
   PubMed Web of Science ®Google Scholar
• Liu J, Mao K, Jiang S, et al. The role of postmastectomy radiotherapy in clinically node-positive, stage II-III breast cancer patients with pathological negative nodes after neoadjuvant chemotherapy: an analysis from the NCDB. Oncotarget. 2016;7(17):24848–24859.
   PubMedGoogle Scholar
• Zell JA, Tsang WY, Taylor TH, et al. Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry. Breast Cancer Res. 2009;11(1):R9.
   PubMed Web of Science ®Google Scholar
• Li J, Gonzalez‐Angulo AM, Allen PK, et al. Triple‐negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer. Oncologist. 2011;16(12):1675–1683.
   PubMed Web of Science ®Google Scholar
• Swisher SK, Swisher SK, Vila J, et al. Locoregional control according to breast cancer subtype and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast-conserving therapy. Ann Surg Oncol. 2016;23(3):749–756.
   PubMed Web of Science ®Google Scholar
• Boileau J, Simmons C, Clemons M, et al. Extending neoadjuvant care through multi-disciplinary collaboration: proceedings from the fourth annual meeting of the Canadian consortium for locally advanced breast cancer. Current Oncol. 2012;19(2):106–114.
   Google Scholar
• Cortazar P, Zhang L, Untch MA, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164–172.
   PubMed Web of Science ®Google Scholar
• Caudle AS, Yu T, Tucker SL, et al. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Breast Cancer Res. 2012;14(3):R83.
   PubMed Web of Science ®Google Scholar
• Pierce LJ, Lippman M, Ben-Baruch N, et al. The effect of systemic therapy on local-regional control in locally advanced breast cancer. Int J Radiat Oncol Biol Phys. 1992;23(5):949–960.
   PubMed Web of Science ®Google Scholar
• Mamounas EP, Anderson SJ, Dignam JJ, et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of national surgical adjuvant breast and bowel project B-18 and B-27. J Clin Oncol. 2012;30(32):3960–3966.
   PubMed Web of Science ®Google Scholar
• Le Scodan R, Selz J, Stevens D, et al. Radiotherapy for stage II and stage III breast cancer patients with negative lymph nodes after preoperative chemotherapy and mastectomy. Int J Radiat Oncol Biol Phys. 2012;82(1):e1–e7.
   PubMed Web of Science ®Google Scholar
• Fei F, Messina C, Slaets L, et al. Tumour size is the only predictive factor of distant recurrence after pathological complete response to neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancers: a sub-study of EORTC 10994/BIG 1-00 phase III trial. Eur J Cancer. 2015;51(3):301–309.
   PubMed Web of Science ®Google Scholar
• Gillon P, Touati N, Breton-Callu C, et al. Factors predictive of locoregional recurrence following neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancer: an analysis of the EORTC 10994/BIG 1-00 study. Eur J Cancer. 2017;79:226–234.
   PubMed Web of Science ®Google Scholar
• Aalders KC, Touati N, Tryfonidis K, et al. Do patients whose tumor achieved a pathological response relapse at specific sites? A substudy of the EORTC 10994/BIG-1-00 trial. Breast Cancer Res Treat. 2018;169(3):497–505.
   PubMed Web of Science ®Google Scholar
• Fayanju OM, Ren Y, Thomas SM, et al. The clinical significance of breast-only and node-only pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT): a review of 20,000 breast cancer patients in the national cancer data base (NCDB). Ann Surg. 2018;268(4):591–601.
   PubMed Web of Science ®Google Scholar
• Low JA, Berman AW, Steinberg SM, et al. Long-term follow-up for locally advanced and inflammatory breast cancer patients treated with multimodality therapy. J Clin Oncol. 2004;22(20):4067–4074.
   PubMed Web of Science ®Google Scholar
• Chen AM, Meric-Bernstam F, Hunt KK, et al. Breast conservation after neoadjuvant chemotherapy: the M.D. Anderson cancer center experience. J Clin Oncol. 2004;22(12):2303–2312.
   PubMed Web of Science ®Google Scholar
• Chatterjee S, Saha A, Arun I, et al. Correlation of clinicopathological outcomes with changes in IHC4 status after NACT in locally advanced breast cancers: do pre-NACT ER/PR status act as better prognosticators? Breast Cancer. 2015;7:381–388.
   PubMed Web of Science ®Google Scholar
• Chou H, Kuo W, Yu C, et al. Impact of age on pathological complete response and locoregional recurrence in locally advanced breast cancer after neoadjuvant chemotherapy. Biomed J. 2019;42(1):66–74.
   PubMed Web of Science ®Google Scholar
• Cho WK, Park W, Choi DH, et al. The benefit of post-mastectomy radiotherapy in ypN0 patients after neoadjuvant chemotherapy according to molecular subtypes. J Breast Cancer. 2019;22(2):285–296.
   PubMed Web of Science ®Google Scholar
• Ring A, Webb A, Ashley S, et al. Is surgery necessary after complete clinical remission following neoadjuvant chemotherapy for early breast cancer? J Clin Oncol. 2003;21(24):4540–4545.
   PubMed Web of Science ®Google Scholar
• Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347(16):1233–1241.
   PubMed Web of Science ®Google Scholar
• Taskin F, Polat Y, Erdogdu IH, et al. Problem-solving breast MRI: useful or a source of new problems? Diagn Interv Radiol. 2018;24(5):255–261.
   PubMed Web of Science ®Google Scholar
• Oh JL, Nguyen G, Whitman GJ, et al. Placement of radiopaque clips for tumor localization in patients undergoing neoadjuvant chemotherapy and breast conservation therapy. Cancer. 2007;110(11):2420–2427.
   PubMed Web of Science ®Google Scholar
• Teichgraeber DC, Martaindale S, Omofoye TS, et al. Immediate migration of biopsy clip markers after upright digital breast tomosynthesis-guided vacuum-assisted core biopsy. Acad Radiol. 2020;27(2):204–209.
   PubMed Web of Science ®Google Scholar
• Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310(14):1455–1461.
   PubMed Web of Science ®Google Scholar
• Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11(10):927–933.
   PubMed Web of Science ®Google Scholar
• Donker M, Van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303–1310.
   PubMed Web of Science ®Google Scholar
• Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer. 2006;106(1):4–16.
   PubMed Web of Science ®Google Scholar
• DiSipio T, Rye S, Newman B, et al. Incidence of unilateral arm lymphoedema after breast cancer: a systematic review and meta-analysis. Lancet Oncol. 2013;14(6):500–515.
   PubMed Web of Science ®Google Scholar
• Schrenk P, Rieger R, Shamiyeh A, et al. Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma. Cancer. 2000;88(3):608–614.
   PubMed Web of Science ®Google Scholar
• Purushotham AD, Upponi S, Klevesath MB, et al. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol. 2005;23(19):4312–4321.
   PubMed Web of Science ®Google Scholar
• Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14(7):609–618.
   PubMed Web of Science ®Google Scholar
• Boughey JC, Ballman KV, Le-Petross HT, et al. Identification and resection of clipped node decreases the false-negative rate of sentinel lymph node surgery in patients presenting with node-positive breast cancer (T0–T4, N1–N2) who receive neoadjuvant chemotherapy: results from ACOSOG Z1071 (Alliance). Ann Surg. 2016;263(4):802–807.
   PubMed Web of Science ®Google Scholar
• Donker M, Straver ME, Wesseling J, et al. Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure. Ann Surg. 2015;261(2):378–382.
   PubMed Web of Science ®Google Scholar
• Janssen NNY, Nijkamp J, Alderliesten T, et al. Radioactive seed localization in breast cancer treatment. Br J Surg. 2016;103(1):70–80.
   PubMed Web of Science ®Google Scholar
• EBCTCG (Early Breast Cancer Trialists’ Collaborative Group). Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383(9935):2127–2135.
   PubMed Web of Science ®Google Scholar
• Whelan TJ, Olivotto IA, Parulekar WR, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015;373(4):307–316.
   PubMed Web of Science ®Google Scholar
• Poortmans PM, Weltens C, Fortpied C, et al. Internal mammary and medial supraclavicular lymph node chain irradiation in stage I–III breast cancer (EORTC 22922/10925): 15-year results of a randomised, phase 3 trial. Lancet Oncol. 2020;21:1602–1610.
   PubMed Web of Science ®Google Scholar
• Fowble BL, Einck JP, Kim DN, et al. Role of postmastectomy radiation after neoadjuvant chemotherapy in stage II-III breast cancer. Int J Radiat Oncol Biol Phys. 2012;83(2):494–503.
   PubMed Web of Science ®Google Scholar
• Buchholz TA, Tucker SL, Masullo L, et al. Predictors of local-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation. J Clin Oncol. 2002;20(1):17–23.
   PubMed Web of Science ®Google Scholar
• Krug D, Lederer B, Seither F, et al. Post-mastectomy radiotherapy after neoadjuvant chemotherapy in breast cancer: a pooled retrospective analysis of three prospective randomized trials. Ann Surg Oncol. 2019;26(12):3892–3901.
   PubMed Web of Science ®Google Scholar
• Shah R, Hunter-Smith AE, Botes A, et al. Does post mastectomy radiotherapy reduce loco-regional recurrence rates in all clinical stages of breast cancer following a complete pathological response to neoadjuvant chemotherapy? A systematic review and meta-analysis of the literature. Breast Cancer Manage. 2020;9(2):BMT38.
   Web of Science ®Google Scholar
• Garg AK, Oh JL, Oswald MJ, et al. Effect of postmastectomy radiotherapy in patients <35 years old with stage II-III breast cancer treated with doxorubicin-based neoadjuvant chemotherapy and mastectomy. Int J Radiat Oncol Biol Phys. 2007;69(5):1478–1483.
   PubMed Web of Science ®Google Scholar
• Wang X, Xu L, Yin Z, et al. Locoregional recurrence-associated factors and risk-adapted postmastectomy radiotherapy for breast cancer staged in cT1-2N0-1 after neoadjuvant chemotherapy. Cancer Manag Res. 2018;10:4105–4112.
   PubMed Web of Science ®Google Scholar
• Matsuda N, Hayashi N, Ohde S, et al. A nomogram for predicting locoregional recurrence in primary breast cancer patients who received breast‐conserving surgery after neoadjuvant chemotherapy. J Surg Oncol. 2014;109(8):764–769.
   PubMed Web of Science ®Google Scholar
• Yang TJ, Morrow M, Modi S, et al. The effect of molecular subtype and residual disease on locoregional recurrence in breast cancer patients treated with neoadjuvant chemotherapy and postmastectomy radiation. Ann Surg Oncol. 2015;22(S3):S495–501.
   PubMedGoogle Scholar
• Vila J, Teshome M, Tucker SL, et al. Combining clinical and pathologic staging variables has prognostic value in predicting local-regional recurrence following neoadjuvant chemotherapy for breast cancer. Ann Surg. 2017;265(3):574–580.
   PubMed Web of Science ®Google Scholar
• Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J clin oncol. 2007;25(28):4414–4422.
   PubMed Web of Science ®Google Scholar
• Symmans WF, Wei C, Gould R, et al. Long-term prognostic risk after neoadjuvant chemotherapy associated with residual cancer burden and breast cancer subtype. J clin oncol. 2017;35(10):1049–1060.
   PubMed Web of Science ®Google Scholar
• Thekkekara RJ, Bharadwaj S, Yadav U, et al. Predicting response to neoadjuvant chemotherapy in nonmetastatic hormone receptor-positive breast cancer using 21-gene breast recurrence score test. J clin oncol. 2019;37(15_suppl):e12093.
   Google Scholar
• Pease AM, Riba LA, Gruner RA, et al. Oncotype DX.sup.[R] recurrence score as a predictor of response to neoadjuvant chemotherapy. Ann Surg Oncol. 2019;26(2):366.
   PubMed Web of Science ®Google Scholar
• Whitworth P, Stork-Sloots L, De Snoo FA, et al. Chemosensitivity predicted by blueprint 80-gene functional subtype and mammaprint in the prospective neoadjuvant breast registry symphony trial (NBRST). Ann Surg Oncol. 2014;21(10):3261–3267.
   PubMed Web of Science ®Google Scholar
• Glück S, De Snoo F, Peeters J, et al. Molecular subtyping of early-stage breast cancer identifies a group of patients who do not benefit from neoadjuvant chemotherapy. Breast Cancer Res Treat. 2013;139(3):759–767.
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov[Internet]. Bethesda (MD): national library of medicine (US). 2000 Feb 29 -. Identifier NCT01901094, comparison of axillary lymph node dissection with axillary radiation for patients with node-positive breast caner treated with chemotherapy; 2013 Jul 17 [cited 2020 Oct 20]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT01901094
   Google Scholar